March 13, 2026

RSV Vaccine Eligibility Expands

Trial data show noninferior immune response in high-risk adults aged 18 to 49 years.

Conexiant

March 13, 2026

Sleep Duration Signals Metabolic Change

Weekend sleep recovery shows mixed metabolic associations depending on weekday sleep duration.

Conexiant

March 13, 2026

Empagliflozin Tested in Real-World Data

Investigators assess whether EMPA-REG findings extend to broader patients with type 2 diabetes.

Conexiant

March 12, 2026

The Oral GLP‑1 Era Has Arrived 

And chromatographers are about to be very busy…

The Analytical Scientist

March 11, 2026

Could Wegovy Raise Optic Nerve Risk?

A pharmacovigilance analysis of FDA adverse event reports finds the strongest ischemic optic neuropathy reporting signal with high-dose semaglutide formulations, with higher adjusted odds reported in men.

Conexiant

March 11, 2026

Childhood Tooth Decay Linked to Heart Risk 

Danish study points to the importance of oral health interventions to protect future cardiovascular health

The Pathologist

March 10, 2026

SGLT2 Inhibitors Linked to Better Outcomes in Diabetes and Cirrhosis

A nationwide cohort study found lower rates of cardiorenal complications and hepatic decompensation

Conexiant

March 10, 2026

AI-Selected Trial Candidates are More Diverse

Could artificial intelligence-enabled medical chart review improve the speed, accuracy, and equity of study enrollment?

The Pathologist

March 09, 2026

Diabetes Risk Assessment: A New Approach

Blood-based epigenetic markers show strong prognostic potential for Type 2 diabetes

The Pathologist

March 06, 2026

Side Effects: Medicine's Blind Spot

Medicine is having a week: new insights on nutrition training, a rethink of “spring fatigue,” evidence that avocados may support artery health, and an AI that can spot rare hormone tumors from a hand photo

Conexiant